Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Division of Nuclear Medicine PET Radiopharmaceutical Production Program
483
•Division of Nuclear Medicine PET Radiopharmaceutical Production Program•September 17, 2025

Division of Nuclear Medicine PET Radiopharmaceutical Production Program – FDA 483, Sep 17, 2025

Record Details

The Division of Nuclear Medicine PET Radiopharmaceutical Production Program received an FDA Form 483 following an inspection conducted on September 16-17, 2025. The document details significant deficiencies in the firm's manufacturing processes, quality assurance, and regulatory reporting for PET drug products.Key violations centered on inadequate production and process controls. Inspectors observed a lack of appropriate parameters for investigating microbial growth, with procedures requiring investigations only above a certain microbial count. Environmental monitoring protocols were found deficient, specifically not requiring surface contact plating in critical sterile environments like the Biological Safety Cabinet where sterility media is handled. Gowning and cleaning procedures were also inadequate, failing to mandate sterile gloves and prevent human hair and skin exposure in ISO-classified areas, with direct observations of non-sterile glove use and exposed hair during product assembly.Furthermore, the facility failed to adhere to its own written quality assurance procedures by not conducting thorough investigations into noted microbial excursions, performing only identification without implementing corrective or preventive actions. A critical regulatory lapse involved the firm's failure to submit Field Alert Reports to the FDA within three working days regarding suspected bacteriological contamination in distributed sterile PET drug products. The firm also lacked documented procedures for submitting these essential reports.These observations, issued under Section 704(b) of the Federal Food, Drug and Cosmetic Act, indicate conditions that could lead to the production of adulterated drugs. The firm is expected to promptly address these findings by implementing comprehensive corrective and preventive actions to ensure the consistent production of safe and quality radiopharmaceutical products and comply with federal regulations.

Company
Division of Nuclear Medicine PET Radiopharmaceutical Production Program
Inspection date
September 17, 2025
Product type
drugs
Office
Detroit District Office
Person
  • Andrew Le (Regulatory Affairs Specialist)
View Company Profile

ID · 2303e633-fd9b-47f7-9219-099797fab256

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Division of Nuclear Medicine PET Radiopharmaceutical Production Program
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.